Gastrointestinal bleeding in a chronic myeloid leukaemia patient precipitated by dasatinib-induced platelet dysfunction: Case report

References

• Cagnetta A, Garuti A, Marani C, Cea M, Miglino M, Rocco I, Palermo C, Fugazza G, Cirmena G, Colombo N, et al. Evaluating treatment response of chronic myeloid leukemia: Emerging science and technology. Curr Cancer Drug Targets 2013;13:779–790
   PubMed Web of Science ®Google Scholar
• Joske D. Chronic myeloid leukaemia: The evolution of gene targeted therapy. MJA 2008;189:277–281
   PubMed Web of Science ®Google Scholar
• Lhermusier T, Van Rothem J, Garcia C, Gratacap MP, Payrastre B. Targeted drug therapy: The platelet side. Platelets 2011;22:479–484
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C, Niederwieser D, Resta D, Capdeville R, Zoellner U, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002;346:645–652
   PubMed Web of Science ®Google Scholar
• Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, et al. Chronic myeloid leukaemia: An update of concepts and management recommendations of European LeukaemiaNet. J Clin Oncol 2009;27:6041–6051
   PubMed Web of Science ®Google Scholar
• Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305:399–401
   PubMed Web of Science ®Google Scholar
• Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, et al. Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 2002;99:1928–1937
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Kantarjian H, Ravandi F, O'Brien S, Thomas D, Vidal-Senmache G, Wierda W, Kornblau S, Cortes J. Bleeding diasthesis in patients with chronic myelogenous leukaemia receiving dasatinib therapy. Cancer 2009;115:2482–2490
   PubMed Web of Science ®Google Scholar
• Rix U, Hantschel O, Durnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood 2007;110:4055–4063
   PubMed Web of Science ®Google Scholar
• Grave M, Goodman V, Kaminskas E, Farrell A, Timmer W, Pope S, Harapanhalli R, Saber H, Morse D, Bullock J, et al. Sprycel for chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia resistant to or intolerant of imatinib mesylate. Clin Cancer Res 2008;14:352–359
   PubMed Web of Science ®Google Scholar
• Ishida Y, Terasako K, Oshima K, Sakamoto K, Ashizawa M, Sato M, Kikuchi M, Kimura S, Nakasone H, Okuda S, et al. Dasatinib followed by second allogeneic hematopoietic stem cell transplantation for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia after the first transplantation. Int J Hematol 2010;92:542–546
   PubMed Web of Science ®Google Scholar
• Ono Y, Mori T, Kato J, Yamane A, Yajima T, Iwao Y, Hibi T, Okamoto S. Hemorrhagic colonic ulcers caused by dasatinib for chronic myelogenous leukemia. Int J Hematol 2010;92:556–558
   PubMed Web of Science ®Google Scholar
• Yhim HY, Kim HS, Lee NR, Song EK, Kwak JY, Yim CY. Bilateral subdural hemorrhage as a serious adverse event of dasatinib in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol 2012;95:585–587
   PubMed Web of Science ®Google Scholar
• Sartor C, Papayannidis C, Chiara Abbenante M, Iacobucci I, Broccoli A, Venturi C, Testoni N, Ferrari A, Martinelli G. Recurrent gastrointestinal hemorrhage in treatment with dasatinib in a patient showing SMAD4 mutation with acute lymphoblastic leukemia Philadelphia positive and juvenile polyposis hereditary hemorrhagic telangiectasia syndrome. Hematol Rep 2013;5:26–27
   PubMedGoogle Scholar
• Chen J, Zheng Z, Shen J, Zhou Y. The combination of thymosin and methylprednisolone for the treatment of a patient with colonic ulcers, subcutaneous nodules, and pleural effusion after dasatinib treatment for chronic myeloid leukemia. Leuk Lymphoma 2010;51:941–943
   PubMed Web of Science ®Google Scholar
• Mustafa Ali MK, Sabha MM, Al-Rabi KH. Spontaneous subdural hematoma in a patient with Philadelphia chromosome-positive acute lymphoblastic leukemia with normal platelet count after dasatinib treatment. Platelets 2014;15:1–4
   Google Scholar
• Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71–86
   PubMed Web of Science ®Google Scholar
• Michelson AD. Antiplatelet therapies for the treatment of cardiovascular disease. Nat Rev Drug Discov 2010;9:154–169
   PubMed Web of Science ®Google Scholar
• Broos K, De Meyer SF, Feys HB, Vanhoorelbeke K, Deckmyn H. Blood platelet biochemistry. Thromb Res 2012;129:245–249
   PubMed Web of Science ®Google Scholar
• Jackson SP. The growing complexity of platelet aggregation. Blood 2007;109:5087–5095
   PubMed Web of Science ®Google Scholar
• Gratacap M, Martin V, Valera M, Allart S, Garcia C, Sié P, Recher C, Payrastre B. The new tyrosine-kinase inhibitor and anticancer drug dasatinib reversibly affects platelet activation in vitro and in vivo. Blood 2009;114:1884–1892
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Han X, Kantarjian H, Cortes J. Tyrosine kinase inhibitor-induced platelet dysfunction in patients with chronic myeloid leukaemia. Blood 2009;114:261–263
   PubMed Web of Science ®Google Scholar
• Mazharian A, Ghevaert C, Zhang L, Massberg S, Watson S. Dasatinib enhances megakaryocyte differentiation but inhibits platelet formation. Blood 2011;117:5198–5206
   PubMed Web of Science ®Google Scholar